FDA's Jenkins: Patient Perspective Paramount In Assessing Risk-Benefit
This article was originally published in The Pink Sheet Daily
OND director stresses need to consider the importance of providing choices, as well as "societal expectations," when making approval decisions.
You may also be interested in...
Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Novartis is emphasizing that the removal of Zelnorm from the market is a suspension rather than a withdrawal
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.